Lerozol®

Letrozole
Cytostatic Aromatase Inhibitor (Aromatase Inhibitor)

Indication:
Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer; Extended adjuvant treatment of early breast cancer in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy ; First-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer; Advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy.

Dosage & Administration:
The recommended dose is one 2.5 mg tablet administered once a day, regardless to meals.

Preparation:
Lerozol® Tablet: Box containing 1x5 tablets in blister pack.



  • Products By Trade Name

  • Products By Generic

  • Products By Therapeutic Class

  • Herbal & Nutraceuticals

  • AgroVet & Pesticides